Low-dose naltrexone is compounded at a fraction of the strength in the commercially available 50 mg naltrexone tablet, which puts every such prescription through the same regulatory sequence under Section 503A of the Federal Food, Drug, and Cosmetic Act: where the bulk drug substance came from, whether the compounded product counts as essentially a copy of a commercially available drug, and whether the file documents the prescriber's basis for that specific strength. A compounding pharmacy that cannot answer all three on the day of an FDA inspection or a state board complaint is already exposed.
The Off-Label Demand for Compounded LDN
No FDA-approved low-dose naltrexone product exists. The FDA-approved naltrexone products, an oral tablet and an extended-release injectable, are indicated for alcohol dependence and opioid dependence at strengths of 50 mg and above. When a prescriber orders naltrexone at a small fraction of that strength for a different use, the prescription is off-label by definition, and the pharmacy that fills it is not operating under any FDA approval of its own. It is operating inside the exemptions Section 503A grants to traditional pharmacy compounding, on the 503A/503B framework's pharmacy side rather than the outsourcing-facility side, which is why the sourcing and copy questions below determine whether the exemption applies.
Bulk Drug Substance Sourcing for Naltrexone
Section 503A permits a bulk drug substance only if it complies with an applicable United States Pharmacopoeia or National Formulary monograph, is a component of a drug the FDA has already approved, or appears on a list the agency has established by regulation, a framework covered in Bulk Drug Substance Sourcing and the Section 503A Lists. Naltrexone hydrochloride is the active ingredient in the FDA-approved oral tablet and the approved extended-release injectable, so a pharmacy sourcing bulk naltrexone as a component of one of those approved drugs is relying on a pathway the statute already recognizes, without needing a separate listing on the 503A bulks list. Section 503A also exempts the compounding pharmacy from the cGMP manufacturing standards that apply to drug makers, though an inspector still tests the sourcing above against the supplier's certificate of analysis and registration status.
The Essentially-a-Copy Question
Section 503A also withholds its exemptions from a pharmacist who compounds, regularly or in inordinate amounts, a drug that is essentially a copy of a commercially available drug product. FDA's January 2018 guidance on the provision sets out a three-part test: the same active pharmaceutical ingredient, a dosage strength the agency treats as the same, similar, or easily substitutable, and the same route of administration. FDA generally treats strengths within 10 percent of each other as similar. A compounded LDN capsule shares naltrexone's active ingredient and its oral route with the commercially available tablet, which leaves strength as the operative question. The statute's own exception covers it: a product is not essentially a copy when a prescriber determines, for an identified patient, that a specific change produces a significant difference for that patient, not merely a general preference for a lower dose.
The statute protects a compounded strength change from the essentially-a-copy restriction only when a prescriber has determined, for a named patient, that the change produces a significant difference, not simply a preference for less drug.
Prescriber Documentation Requirements
The exception does the legal work, but only the file proves it was invoked. A defensible LDN record identifies the patient by name, carries a valid prescription for the specific compounded strength, and states the prescriber's basis for that strength rather than leaving the pharmacy to infer one. Common FDA Form 483 Observations at 503A Compounding Pharmacies catalogs the component, beyond-use-date, and recordkeeping findings FDA cites at 503A pharmacies. The beyond-use date on the compounded capsule needs a documented stability basis in the compounding record behind it. Most compounded LDN is a non-sterile oral capsule, so the sterile and hazardous-drug standards in USP 797/800 typically do not apply, though the facility's non-sterile compounding and recordkeeping obligations still do.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving an FDA Form 483, a state board of pharmacy inquiry, or any other government request tied to a low-dose naltrexone order. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance's compounding pharmacy attorneys defend 503A pharmacies in FDA inspections, state board proceedings, and essentially-a-copy disputes, including matters built on low-dose naltrexone and other off-label compounded strengths. Health Law Alliance has represented 2,500+ clients nationwide. If your pharmacy is sourcing, documenting, or defending a low-dose naltrexone program, schedule a free consultation with HLA's 503A compounding defense attorneys before an inspector or board investigator raises the essentially-a-copy question for you.





